Clinical trials: Age Factor
Hemophilia
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in…
- Trial name
- ATLAS-NEO (NCT05662319)
- Testing
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Where
- 50 sites in United States, Canada and 15 more
- Volunteers
- 91 people
- Sponsor
- Sanofi
Exudative Age Related Macular Degeneration
Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
Optical Coherent Tomography Angiography (OCTA)-Directed PDT Triple Therapy for Treatment-Naïve Patients with Exudative Age-related Macular Degeneration (ARMD) versus Standard of Care Anti-VEGF Monotherapy
- Trial name
- NCT04075136
- Testing
- Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Neovascular Age-related Macular Edema, Diabetic Macular Edema
Anti-VEGF in Real-world
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of…
- Conditions
- Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane, Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05222633
- Testing
- Ranibizumab, Aflibercept, Conbercept
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wenbin Wei
Severe Hemophilia A
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
This is a Phase IIIb, multicenter, open-label, single-arm study of prophylactic emicizumab in previously untreated and minimally treated patients at study enrollment from birth to ≤12 months of age with severe hemophilia A…
- Trial name
- HAVEN 7 (NCT04431726)
- Testing
- Emicizumab
- Where
- 32 sites in United States, Australia and 12 more
- Volunteers
- 55 people
- Sponsor
- Hoffmann-La Roche
Exudative Age-Related Macular Degeneration
ESBA1008 Microvolume Study
The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macular degeneration (AMD).
- Trial name
- NCT01849692
- Testing
- ESBA1008 solution, Ranibizumab
- Volunteers
- 107 people
- Sponsor
- Alcon Research
Wet Age-Related Macular Degeneration
Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
The purpose of the study was to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF protein levels in treatment naïve wet neovascular Age-related Macular Degeneration (wAMD) patients in a…
- Trial name
- TIDE AMD (NCT02257632)
- Testing
- Ranibizumab 0.5 mg, Aflibercept 2 mg
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
Comparison of Predictive Factors Related to Coronary Artery Disease
In Taiwan, heart disease and cerebrovascular disease ranked the second and third of ten leading causes of death in female in 2007; half of these deaths is due to coronary artery disease (CAD).
- Trial name
- NCT01136343
- Testing
- lifestyle modified project
- Where
- Taiwan
- Volunteers
- 130 people
- Sponsor
- Taipei Medical University WanFang Hospital
Neovascular Age-related Macular Degeneration(nAMD)
CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
Age-related macular degeneration (AMD) is a progressive disease leading to severe and irreversible vision loss of which the neovascular AMD (nAMD) accounted for 90% blindness in AMD.
- Trial name
- NCT06031727
- Testing
- HG202
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
Infertility, Female
The Role of ICSI in Non-male Factor Infertility in Advanced Maternal Age
The use of Intracytoplasmic sperm injection (ICSI) has increased in the last decades regardless of the cause of infertility. Despite the increased use there is no clear evidence that ICIS is more effective than conventional in…
- Trial name
- ICSI (NCT03370068)
- Testing
- ICSI, Conventional IVF
- Where
- Israel
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Dr. Tal Miller-Elkan
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
- Trial name
- DAYBREAK (NCT06556368)
- Testing
- Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 675 people
- Sponsor
- Kodiak Sciences Inc
Macular Polypoidal Choroidal Vasculopathy (PCV)
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
This study is a 60-week, two-arm, randomized, open-label, active-controlled, multi-center study in patients with Polypoidal choroidal vasculopathy (PCV) who have not previously received anti-Vascular endothelial growth factor…
- Trial name
- PROUD (NCT05666804)
- Testing
- Brolucizumab 6mg
- Where
- 15 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Vitreomacular Interface
Intravitreal Anti-vascular Endothelial Growth Factor Administration and Its Influence on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration
Purpose: To assess the influence of intravitreal anti-vascular endothelial growth factor (anti-VEGF) administration on vitreomacular interface- and retinal morphology in eyes with neovascular age-related macular degeneration…
- Trial name
- NCT03680326
- Testing
- OCT
- Volunteers
- 43 people
- Sponsor
- Hospital Hietzing
Age Related Macular Degeneration
Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting
Neovascular age-related macular degeneration (nAMD), also called wet AMD, can cause serious vision loss. While anti-VEGF (anti Vascular Endothelial Growth Factor) treatments such as ranibizumab help many patients, about 20 40%…
- Trial name
- M-VIVA (NCT07249216)
- Testing
- Faricimab, Ranibizumab
- Where
- Singapore
- Volunteers
- 117 people
- Sponsor
- Singapore National Eye Centre
Age-related Macular Degeneration
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina.
- Trial name
- NCT00539734
- Testing
- ranibizumab
- Where
- Thailand
- Volunteers
- 25 people
- Sponsor
- Prince of Songkla University
Wet Macular Degeneration
Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor
Patients with neovascular age-related macular degeneration who do not respond to usual treatment with conventional medications may respond to a new drug of the same class which is designed to block a larger fraction of…
- Trial name
- MACBETH (NCT01896284)
- Testing
- 0.5mg aflibercept
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Barcelona Macula Foundation
Macular Degeneration
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
- Trial name
- VIEW 2 (NCT00637377)
- Testing
- Ranibizumab, Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- Where
- 189 sites in Argentina, Australia and 24 more
- Volunteers
- 1,240 people
- Sponsor
- Bayer
Hemophilia A, Hemophilia B
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called marstacimab) for the potential treatment of hemophilia in pediatric patients.
- Trial name
- BASIS KIDS (NCT05611801)
- Testing
- marstacimab
- Where
- 63 sites in United States, Argentina and 21 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Neovascular Age Related Macular Degeneration
NVAMD Satellite Study
Intravitreal delivery of anti-vascular endothelial growth factor (VEGF) drugs has revolutionized the management of neovascular age-related macular degeneration (NVAMD).
- Trial name
- NCT02251366
- Testing
- Physician-guided diagnostic
- Where
- 5 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Age Related Macular Degeneration
Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes
Age Related Macular Degeneration (AMD) is the leading cause of blindness in North America. This condition causes a progressive loss of central vision, the part of your vision that allows you to read, drive and see images in sharp…
- Trial name
- NCT01363570
- Testing
- Ranibizumab
- Where
- 2 sites in Canada
- Volunteers
- 70 people
- Sponsor
- McMaster University
Age-related Macular Degeneration
Cytokeratin 8 Level in Age-related Macular Degeneration
The investigators will evaluate the concentrations of cytokeratin 8 in aqueous humor in eyes with exudative age-related macular degeneration (AMD) before therapy with intravitreal Ranibizumab, and identify associations with…
- Trial name
- NCT02707575
- Testing
- Ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 58 people
- Sponsor
- Gangnam Severance Hospital